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Immunization plays a critical role in prevent-ing and mitigating infectious disease outbreaks, protecting the persons receiving the vaccination 
and, by interrupting the transmission of disease, the 
entire population. In today’s interconnected world, 
where infectious diseases rarely stay contained within 
national borders, realizing global health security 
requires global immunization efforts to prevent infec-
tious disease throughout the world. This global pre-
vention effort will require attention to public health 
law. Public health law can expand immunization as 
essential to global health security, and global health 
security can serve as a catalyst for reforming public 
health law to expand immunization. 
While robust research exists on the clinical and epi-
demiological efficacy of immunization, relatively few 
studies have analyzed how immunization laws affect 
public health outcomes, with little focus on these pub-
lic health laws in low- and middle-income countries. 
Such legal epidemiology analysis can facilitate the 
comparative examination of national immunization 
laws necessary to understand the public health influ-
ence of varied legal approaches, identify the crucial 
attributes of national immunization laws, and facili-
tate the harmonization of effective legal practices. 
Policy surveillance is a necessary precursor for this 
research, providing comparative legal datasets that 
track the presence and attributes of immunization 
laws — across countries and over time. From these 
legal datasets, researchers can examine associations 
between these legal data and epidemiological data 
(such as vaccination rates and other health outcomes) 
to determine the effect of vaccination law as a deter-
minant of public health.
This article provides a foundation for policy surveil-
lance research on national immunization law — exam-
ining national implementation of the Global Health 
Security Agenda (GHSA) by comparing the scope and 
content of immunization laws across 20 Sub-Saharan 
African countries. Part I reviews the evolving impor-
tance of immunization to public health and the legal 
frameworks necessary to support immunization cov-
erage. As a basis for studying GHSA implementation 
through national law, Part II describes the methods 
by which this study (1) developed a legal framework 
that maps the attributes pertinent to immunization 
law; (2) created an assessment tool to determine 
the presence or absence of specific legal authorities; 
and (3) applied the assessment tool to code national 
immunization laws. Based upon this comparative cod-
ing research, Part III analyzes the scope and content 
of immunization laws across Sub-Saharan African 
countries, highlighting examples of national laws that 
meet identified attributes to prevent public health 
emergencies and protect public health. Part IV dis-
cusses the importance of legal epidemiology in linking 
these national immunization laws with public health 
outcomes, providing a public health justification for 
reforming national public health law. This article con-
cludes by discussing the need for additional empiri-
cal research capable of assessing the role of national 
public health law as a determinant of global health 
security. 
Tsion Berhane Ghedamu, M.S.P.H, is a Program Manager 
at the Aspen Institute. Benjamin Mason Meier, J.D., LL.M., 
Ph.D., is an Associate Professor of Global Health Policy at the 
University of North Carolina at Chapel Hill and a Scholar 
at the O’Neill Institute for National and Global Health Law.
I. Background
Immunization refers to the process by which an indi-
vidual intentionally develops resistance (or immunity)
to one or more communicable diseases.1 The most com-
mon form of immunization — vaccination — involves
the introduction of a product, often an inactive form of
an infectious agent, to prepare a person’s immune sys-
tem to fight a disease without subjecting that person
to the disease symptoms.2 While only those receiving a
vaccination develop immunity to the disease, individ-
ual vaccination can provide population-level protec-
tion through “herd immunity.”3 Herd immunity occurs
where even those without immunity to a disease are
protected from exposure because a sufficient percent-
age of the population is immune, thereby interrupting
the transmission of an infectious agent.4
Immunization has become one of the most suc-
cessful public health interventions in human history, 
responsible for the greatest reductions in worldwide 
morbidity and mortality.5 Once Edward Jenner devel-
oped the first vaccine against smallpox in 1796,6 small-
pox vaccination spread throughout the world along-
side other public health measures; by 1979, smallpox 
— a disease that had been responsible for roughly 300 
million deaths in the twentieth century — was eradi-
cated.7 Seeking to replicate this success, global eradica-
tion campaigns have been developed for a wide range 
of vaccine-preventable diseases, including measles, 
rubella, and polio. Widespread vaccination against 
polio has reduced the number of reported cases from 
an estimated 350,000 in 1988 to only 37 in 2016.8
Public health law is necessary to assure widespread 
vaccination,9 and global governance institutions have 
sought to coordinate national immunization laws as 
a framework for global health security.10 These law 
reforms have been supported by national governments, 
international organizations such as the World Health 
Organization (WHO), private organizations such as the 
Bill and Melinda Gates Foundation, and public-private 
partnerships such as Gavi, the Vaccine Alliance.11 Yet, 
even as immunization is increasingly seen as a human 
right for all, millions continue to die each year from 
vaccine-preventable diseases,12 creating an imperative 
under the GHSA to reform immunization law as a basis 
to facilitate vaccination and prevent disease. 
A. Developing the GHSA
Given weaknesses in global efforts to control infectious
disease, the GHSA was launched in February 2014 to
“prevent, detect and effectively respond to infectious
disease threats, whether naturally occurring or caused
by accidental or intentional release of dangerous patho-
gens.”13 Seeking to fill gaps in national capacity to con-
trol infections disease, representatives from 32 nations
and 5 health organizations established key GHSA
objectives to improve the global community’s capa-
bility to prevent, detect, and respond to public health
emergencies.14 These objectives would be translated in
May 2014 into 11 “action packages,” which identify pri-
ority technical areas for global health security.15
The action package for immunization (prevent 4) 
was seen as essential to the prevention of global health 
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security threats. In reducing infectious disease out-
breaks, the five-year target for this action package is 
for nations to develop a “functioning national vaccine 
delivery system — with nationwide reach, effective 
distributions, access for marginalized populations, 
adequate cold chain, and ongoing quality control — 
that is able to respond to new disease threats.”16 As 
a proxy indicator of immunization for vaccine-pre-
ventable diseases, GHSA implementation is assessed 
based upon at least 90% national coverage of measles-
containing vaccine. While the GHSA does not address 
immunization for some of the most pressing public 
health concerns, the vaccination authority to address 
global health security threats can have broad applica-
tion to a wide array of vaccine-preventable diseases. 
Although nations took few initial steps to imple-
ment the GHSA, the GHSA Action Packages received 
a dramatic increase in political support following the 
2014-2015 Ebola outbreak in West Africa.17 This Ebola 
epidemic revealed weaknesses of existing global health 
governance institutions to respond effectively to pub-
lic health emergencies.18 When the Ebola outbreak 
occurred, WHO failed to act with sufficient urgency, 
leaving member countries without clear direction or 
sustained support.19 The global response to the Ebola 
epidemic was reflective of the tendency toward fleeting 
investments in global health, with increased resources 
and capabilities declining in the immediate aftermath 
of the epidemic.20 These shortcomings in the global 
response created an imperative to address national 
gaps in disease control authorities, with many gov-
ernments thereafter demanding GHSA action plans 
as a “national security priority.”21 Policymakers devel-
oped a five-year timeline for GHSA implementation 
(from 2015 to 2019) and requested that national gov-
ernments create country-specific roadmaps to meet 
each action package as a basis to prevent, detect, and 
respond to infectious disease threats.22
B. The Need for National Public Health Law Reforms
The GHSA is premised on a need for strong national
health systems, which require robust national legal
frameworks that implement the minimum standards
set out under global health policy.23 Although many
nations have enacted laws to promote public health,
existing laws may not be adequate to address the rate
at which infectious disease epidemics can spread a
cross borders.24 Gaps in global health law have ham-
pered responses to recent public health emergencies
— including the SARS, Ebola, and Zika outbreaks —
making it difficult, among other things, to quarantine
infected or suspected cases, prescribe novel treat-
ments, and coordinate responses across nations.25
Many national laws lack clear authorities to control
epidemics, yet it is at this national level where legal 
reforms can have the greatest impact on public health 
emergencies.26
Global health governance has only recently come to 
understand the importance of national public health 
law to infectious disease control.27 While WHO, the 
World Organization for Animal Health (OIE), and 
the Food and Agriculture Organization of the United 
Nations (FAO) have recognized the importance of 
national law to reduce health risks at the “human-
animal-ecosystems interfaces” under a “One Health” 
approach, existing international legal frameworks 
such as the WHO International Health Regulations 
(IHR) have yet to be fully implemented at the national 
level.28 The need for immunization laws in strength-
ening health security at the national level is also essen-
tial in the implementation of the IHR.29 Despite the 
promise that the IHR would harmonize national leg-
islation for detecting and responding to public health 
emergencies of international concern, many nations 
have not yet undertaken the legal reforms to ensure 
necessary government authority.30 As seen among 
countries at the center of the 2014-2015 Ebola epi-
demic (Guinea, Liberia, and Sierra Leone), while these 
countries have long been bound by the IHR as WHO 
Member States, they nevertheless lacked the health 
systems and public health laws necessary to address 
Ebola.31
Law has a foundational role in establishing the 
national authorities essential to assuring immuniza-
tion in accordance with the GHSA.32 Beyond man-
datory vaccination requirements, national laws can 
prescribe immunization guidelines, including: the 
specific  vaccines to mandate; which populations 
require a given vaccine (e.g., children, health work-
ers); whether to prioritize specific groups (where 
resources are scarce); the most effective or efficient 
vaccine delivery methods; the immunization sched-
ule to ensure effective public health protection; time-
frames for reestablishing a vaccination schedule (espe-
cially after interruptions or delays in immunization); 
vaccine production, cost, safety, and liability; and even 
public education, communication, and incentives to 
increase immunization rates.33 The public percep-
tion of the importance and safety of vaccinations will 
affect the ability of a country to efficiently vaccinate 
the population, but policymakers must have legal sup-
port, especially in low- and middle-income countries 
that lack comprehensive public health authorities.34 
By focusing on GHSA implementation through the 
multisectoral national laws necessary for immuniza-
tion, it is possible to learn from weaknesses of legal 
frameworks in preventing public health emergencies, 
ensuring that such weaknesses do not undermine 
national efforts to prevent future threats to global 
health security.
II. Methods
In order to analyze the scope and content of immuni-
zation laws, this research:
1. Delineated the attributes of immunization laws,
developing a policy surveillance framework.
2. Created an assessment tool to identify the rel-
evant attributes of immunization laws.
3. Coded immunization laws across 20 Sub-
Saharan countries, comparing the content of
national immunization laws based upon identi-
fied attributes.
To determine the presence and characteristics of 
national laws supporting the GHSA Action Package 
on immunization, this study first developed a policy 
surveillance framework to identify specific attributes 
of national law relevant to immunization. This frame-
work was developed through a comprehensive legal 
and public health literature review to characterize 
existing knowledge of successful legal approaches to 
implement GHSA immunization targets. Comple-
mented by an examination of specific immunization 
laws from a variety of high-, middle-, and low-income 
countries, experts in immunization law reviewed 
these attributes to assure that they accurately and suf-
ficiently captured the most salient features of national 
immunization laws. 
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Based on this legal framework, the study then cre-
ated an assessment tool in LawAtlas (http://lawatlas.
org/), a policy surveillance program, outlining ques-
tions to identify the content of pertinent attributes of 
national immunization laws. These coding questions 
allowed for either binary (yes or no) or categorical 
(multiple answers) responses. The questions were 
organized hierarchically, with multiple layers of ques-
tions allowing for greater detail about the attributes 
of a national law. For example, while a top-level ques-
tion might ask whether the law requires individuals 
to receive a vaccination, lower-level questions might 
ask to whom the mandate applies and what diseases 
are covered. 
Applying this assessment tool to national laws, this 
study mapped the national immunization legal land-
scape in 20 Sub-Saharan African countries, including 
Ebola-affected countries (in the 2014-2015 outbreak: 
Guinea, Liberia, and Sierra Leone); countries classi-
fied by the U.S. Centers for Disease Control and Pre-
vention (CDC) as high-risk countries (Benin, Demo-
cratic Republic of Congo, Gambia, Ghana, Guinea 
Bissau, Mauritania, Nigeria, and Togo); and coun-
tries independently prioritized by the CDC under 
GHSA commitments (Burkina Faso, Cameroon, Cote 
d’Ivoire, Ethiopia, Kenya, Mali, Senegal, Tanzania, 
and Uganda). 
To facilitate this policy surveillance, researchers 
employed a multistep, redundant process to identify 
and collect relevant national laws, regulations, and 
other codified materials through online sources, the 
foreign law collection in the U.S. Library of Congress 
Law Library, and in-country sources in national min-
istries. This overlapping process sought to ensure 
that any failure to identify relevant laws indicated the 
absence of such laws. 
Table 1
Attributes of Law across 20 Sub-Saharan Countries
Once identified laws were collected, two trained 
policy researchers redundantly coded each national 
law using the coding questions in the assessment tool. 
This comparative analytic coding sought to classify 
specific legal attributes in national laws through an 
objective, rather than interpretive, examination of the 
law, thereby allowing future research to replicate this 
study and extend the dataset longitudinally. Disagree-
ments among coders were discussed and resolved by 
consensus, making revisions to coding questions and 
answers where necessary to ensure consistent coding. 
This iterative coding process ensured a high-level of 
consistency among coders and increased intercoder 
reliability. 
Notwithstanding the methodological rigor detailed 
above, this policy surveillance study has several limi-
tations. Because many national laws are not pub-
licly available or adequately disseminated, even in-
country collection and verification cannot guarantee 
that a legal dataset includes all relevant laws in the 
examined countries. Moreover, this study sought to 
analyze only codified laws and regulations, and as a 
result, the content of this law may not fully reflect the 
“on-the-ground” reality of immunization. Yet despite 
these limitations, this comparative study — the first 
analytic coding study of national immunization laws 
— provides a baseline assessment of national immu-
nization authority that can facilitate legal epidemiol-
ogy research and public health law reforms. 
III. Results
Assessing the legal environment for immunization 
across 20 Sub-Saharan African countries, this coding 
analysis focused on the four attributes of immuniza-
tion law categorized in Table 1: vaccine requirements, 
supply chains, vaccine administration, and medicines 
quality & manufacturer liability.
Of the 20 examined countries, this study found six 
countries without any immunization authority under 
national law — Cameroon, Cote d’Ivoire, Democratic 
Republic of Congo, Gambia, Guinea, and Mauritania 
— calling into question the importance of laws to the 
implementation of international immunization imper-
atives. For example, the Democratic Republic of Congo 
has no codified immunization laws, and yet in a recent 
Ebola outbreak, the government (together with local 
and international partners, including WHO), adminis-
tered an experimental Ebola vaccine in regions where 
cases were reported.35 Nevertheless, law and policy are 
distinctive tools for the protection of communities, 
and the promulgation of public health law is crucial 
to the enabling authorities of governmental public 
health systems.36 The continuing lack of legal author-
ity will present a challenge to national capacity to real-
ize vaccination requirements — especially in times of 
emergency. National law reform will thus be essential 
in assuring vaccination rates and underlying systems 
for vaccine implementation. Securing the promise of 
the GHSA, the following attributes and examples of 
immunization law can provide government authority 
to prevent disease.37
A. Vaccine Requirements
Enabling legal authority provides a government with
the power to regulate vaccinations, integrating vac-
cine requirements into national public health systems.
Such laws allow for evidence-based vaccine guidelines
to be set by either a governmental or non-governmen-
tal agency. Immunizations are essential to reducing
epidemic-prone diseases, and these legal authorities
provide governments with the ability to ensure that
proper vaccination policies are implemented. Within
the examined countries, a number of national laws
have enabled vaccination offices to coordinate, moni-
tor, and implement national vaccination policies,
establishing the authorized institutions to control all
vaccination services.38 Countries can give full author-
ity to their designated health39 ministers or ministries
to ensure the creation and implementation of immu-
nization policy, as seen where Nigeria40 in 2014 pro-
vided the National Council on Health with the author-
ity to ensure that all children under five and pregnant
women must be vaccinated against infectious diseases.
National Health Bill, 2014 (Nigeria) 
(1) The National Council which shall be the high-
est policy making body in Nigeria on matters
relating to health, shall:
(i) ensure that children between the ages of zero
and five years and pregnant women are immu-
nized with vaccines against infectious diseases.
Rather than delegating to specific institutions, other 
national laws detail the specific guidelines around 
dosage and implementation of vaccination under law. 
In this latter category,41 Mali’s 2008 Arrête Intermin-
istériel Fixant La Liste Des Vaccinations Obligatoires, 
Leurs Calendriers et Les Conditions D’administration 
Des Vaccins has established vaccine regulations around 
dosage and implementation of immunizations within 
public health institutions, with specific immunization 
requirements for students against Yellow Fever, Hepa-
titis B, and Tetanus: 
Arrête Interministériel Fixant La Liste Des 
Vaccinations Obligatoires, Leurs Calendriers 
et Les Conditions D’administration Des Vac-
cins, 2008 (Mali)
Chapitre 2: Des conditions d’administration  
des vaccins
Article 5: L’administration des vaccins a lieu 
dans les établissements de santé publics centre de 
santé de collectivités territoriales, Centre de santé 
de Référence, Etablissements Publics Hospital-
iers et Etablissements de Santé privés partici-
pant au service public dont les Centre de Santé 
Communautaire.
Toutefois, les agents de santé peuvent se déplacer 
dans les endroits précis, convenus avec les bénéfi-
ciaires potentiels, pour administrer les vaccins à 
des moments déterminés de commun accord.
Article 6: Les doses de vaccins nécessaires par 
type de vaccins sont:
• le BCG et le vaccin contre la rougeole sont
administré en dose unique;
• le vaccin contre la poliomyélite est administré
en 4 doses dont la toute première est désigné
dose zéro;
• les vaccins contre la coqueluche, la diphtérie,
hépatite B, le tétanos, la pneumonie à hémo-
philes influenze B sont administrés en 3 doses
Article 7: Les intervalles entre les doses de 
vaccins sont:
• administration de la première dose des vaccins
à doses multiples est séparée de la vaccination
contre la tuberculose et de la 1ère dose de vaccin
contre la poliomyélite de 4 semaines, au moins;
• un intervalle de 4 semaines, au moins sépare
les administrations des vaccins à doses
multiples;
• le 1er rappel des vaccins à doses multiples est
fait à l’âge de 16 semaines;
• Le 2ème rappel est fait au plutôt à 6 ans et au
plus tard, à 7 avant d’entrée à l’école;
• Lors de leur inscription à l’école, les enfants
bénéficient de la vaccination contre la fièvre
jaune, hépatite B et le tétanos.
Ghana similarly enables authorization of immuni-
zations through its Vaccination Act of 1919, which 
provides the Director of the Health Service with the 
ability to regulate the time and location at which indi-
viduals must be vaccinated and the method by which 
these vaccinations are to be distributed. 
The Director also has the ability to regulate the 
inspection of vaccines and ensure treatment of indi-
viduals after vaccinations. Further, the law provides 
the Director with the authority to regulate public vac-
cinators and provide the conditions under which they 
are able to vaccinate. 
Vaccination Act, 1919 (Ghana) 
4. Regulations by Deputy Director of Health
Service
The Director-General of the Service may, subject
to the approval in writing of the Minister by
legislative instrument, make Regulations with
respect to
(a) the times and places of attendance of per-
sons on public vaccinators for the purposes of
vaccination;
(b) the evidence to be accepted of successful vac-
cination, including inspection of the results of
vaccination;
(c) the supply of lymph to public vaccinators;
(d) the method of vaccination by public
vaccinators;
(e) the treatment of persons after vaccination;
and
( f) the functions of assistant public vaccinators,
and the limitations and condition under which
those functions shall be performed.
Through this authority, these vaccination require-
ments can provide for vaccination mandates and 
detail any permissible exemptions from mandatory 
vaccination. 
1. mandatory vaccination
The success of vaccination programs is only attain-
able on the basis of high rates of immunization cover-
age among vulnerable populations, and governments
throughout the world have authorized mandatory
vaccination policies to produce these high rates and
ensure the herd immunity42 necessary to protect
populations.43 Mandatory vaccination has a long his-
tory, dating back to 1806, when the Napoleonic Prin-
cipalities of Piombino and Lucca enacted regulations
requiring vaccination against smallpox.44 Through-
out the 19th century, numerous European nations
enacted similar compulsory vaccination laws,45 and at
the start of the 20th century, Massachusetts became
the first state in the United States requiring the gen-
eral public to be vaccinated against smallpox.46 While
such mandates were and remain controversial, their
legality has been largely upheld. For example, in the
seminal 1905 case of Jacobson v. Massachusetts, the
US Supreme Court upheld a Massachusetts state law
allowing municipal boards of health to compel vacci-
nation against smallpox, holding that a state’s police
powers “must embrace … such reasonable regula-
tions established directly by legislative enactment as
will protect the public health and public safety.”47 The
Court recognized that an individual’s liberty interest
against compulsory vaccination must yield to reason-
able restraints for the common good when such lib-
erty would threaten the health and safety of others.48 
Subsequent cases have bolstered the justification for 
compulsory vaccination laws, finding that strict, well-
enforced vaccination mandates significantly reduce 
disease incidence rates.49
The majority of the 20 sub-Saharan countries in 
this study have laws mandating vaccinations for all 
children. Nevertheless, these laws can differ on the 
appropriate age at which a child should be immu-
nized. Countries such as Tanzania50 and Togo51 require 
infants to be immunized within the first twelve months 
while Ghana requires vaccination within the first 
three months.52 The specific immunizations required 
also can differ by country. A country such as Liberia 
requires children to be immunized “against poliomy-
elitis, smallpox and measles …”53 while Mali requires 
vaccinations “contre la coqueluche, la diphtérie, hépa-
tite B, le tétanos, la pneumonie à hémophiles influenze 
B sont administrés en 3 doses.”54 Rather than specify-
ing diseases under law, several countries provide their 
Minister of Health with the authority to select the 
required vaccines. 
Code de la Sante, 2009 (Togo)
Art. 64 - L’administration des vaccins est obliga-
toire au cours de la première année de vie. Les 
différents rappels de ces vaccins sont également 
obligatoires dans les délais requis.
Un arrêté du ministre chargé de la Santé définit 
chaque fois que de besoin la liste de ces vaccins. 
Les parents ou les tuteurs sont personnellement 
tenus de faire vacciner leurs enfants.
In cases of public health emergencies, many countries 
have codified an emergency mandate for supplemen-
tal mandatory vaccination requirements. Nations 
such as Liberia, Uganda, and Nigeria allow for their 
authorized minister to conduct compulsory immuni-
zation in either a specific area or the entire country in 
cases of emergency. 
Public Health Act, 1935 (Uganda) 
39. Vaccination of persons in or entering
Uganda.
(1) After the introduction of this Act:
(a) the Minister may by statutory order declare
any area to be a compulsory vaccination area
and shall in the order specify a period in which
the vaccination of all unvaccinated persons
dwelling in the area shall take place;
(b) every unvaccinated adult and the parent or
guardian of every unvaccinated child in any
area declared to be a compulsory vaccination
area shall cause himself or herself and the child 
to be vaccinated within the period specified; 
(c) every unvaccinated adult and the parent or
guardian of every unvaccinated child entering
Uganda shall cause himself or herself and the
child to be vaccinated within two months.
These emergency mandates are limited in some cases 
to a specific infectious disease.55 To ensure that man-
datory vaccinations are received, many of these laws 
require that documentation be presented to indi-
viduals after vaccinations. Countries such as Kenya, 
Ghana, and Uganda mandate that public vaccinators 
or medical providers who have performed a vaccina-
tion to provide a certificate of successful vaccination 
to the adult or child. 
This documentation allows governments to take 
action for non-compliance with vaccination. To 
ensure enforcement, many of these laws also include 
penalties for non-compliance, including either a fine 
or imprisonment.56
2. exemptions from vaccination
Over the past decade, researchers in many parts of
the world have recognized an increase in individual
objections to vaccination.57 These increasing objec-
tions to vaccines, threatening herd immunity to dis-
eases, has amplified the debate around exemptions
to vaccination requirements. Throughout the world,
exemptions to vaccinations are often permitted under
law based on health reasons, religious beliefs, or phil-
osophical objections.58 Almost all countries explicitly
allow exemptions necessary for health, usually given
to individuals who have suppressed immune systems,
are allergic to the vaccine, or might have medical con-
traindications with the vaccine.59 Beyond medical
exemptions, further exemptions may allow large pop-
ulations to remain unimmunized, with higher exemp-
tion rates threatening higher disease risk.60 Because of
this, laws will often allow the government to limit vac-
cination exemptions (other than health exemptions)
in cases of public health emergencies, with individuals
who object to vaccination during emergencies either
quarantined or isolated to stop any spread of the dis-
ease. Sub-Saharan countries that were assessed in this
study do not have broad exemption laws, and any per-
missible objections to vaccinations were connected to
health exemptions. Both Kenya61 and Ghana62 have
laws that allow exemptions from vaccination man-
dates, but only based on a certificate given to them by
a provider that states the adult or child is not fit to be
vaccinated.
Public Health Law, 1986 (Kenya) 
107. Person unfit for vaccination
(1) If any public vaccinator or medical practi-
tioner is of opinion that any adult or child is not
in a fit state to be vaccinated, he shall give to the
adult or to the parent or guardian of the child a
certificate under his hand according to Form No 1
in the Schedule, or to the like effect, that the adult
or child is then in a state unfit for vaccination.
While limiting individual freedom of choice, these 
limited exemptions to vaccination mandates serve 
to protect the public by supporting herd immunity 
against infectious disease.
B. Supply Chain
The production and distribution of vaccines requires
a high level of quality control throughout the entire
supply chain. Policies must address the need for trans-
portation, storage, and the secure supervision of vac-
cines to safeguard vaccine administration.63 Laws can
provide requirements around licensure, supply, and
production of vaccines to ensure the safety of these 
vaccines.64 Licensing regulations assure that each 
individual in the supply chain is trained on proper 
vaccine handling and storage. The supply and dis-
tribution of vaccines are in large part dependent on 
licensure within the market, and governments with-
out robust licensure policies are dependent on license 
policies in the country of the manufacturer. 65 The law 
can also provide incentives for vaccine production and 
stockpiles for future emergencies. For example, in case 
of pandemic, there would arise a need to conduct mass 
vaccinations in a short period, and inventories of vac-
cines would enable a nation to distribute immuniza-
tions quickly. Thus, laws to manage vaccine stockpiles 
can also be extremely important — either in a pub-
lic health emergency response or in filling gaps dur-
ing vaccine storages.66 This necessary infrastructure 
must be in place before an emergency occurs. Policy-
makers need to create a system under national law in 
which the supply of vaccines will be able to meet the 
public’s need in any situation, including the need for 
consistent vaccination supplies, stable stockpiles, and 
a steady number of providers. Periodically updated 
strategy and implementation plans must be created to 
ensure efficient and flexible measures during times of 
emergency. 
Yet very few of the examined countries have laws 
addressing the supply chain. The countries with laws 
around vaccine supplies require direct government 
management of a national vaccine stockpile, with 
regulations that demand the safety and quality of vac-
cines at all stages of the supply chain. Kenya67 and 
Sierra Leone68 require a steady supply of drugs and 
medical supplies in their public health facilities and 
a requirement that essential medicines must also be 
maintained in reserves at all times. 
National Pharmaceutical Procurement Unit 
Act, 2012 (Sierra Leone) 
4. (1) The object for which the Unit is established
is to provide an effective, efficient and transpar-
ent environment for the supply of essential medi-
cines of requisite quality, efficacy, accessibility,
and affordability in public health institutions 
throughout Sierra Leone. 
(2) Notwithstanding the generality of subsection
(1), it shall be the function of the Unit to:
(a) procure essential medicines and medical con-
sumables of requisite quality and efficacy for and
on behalf of all public health facilities through-
out Sierra Leone;
(b) receive as donation, store and distribute
essential medicines and medical consumables of
requisite quality and efficacy for and on behalf
of all public health storage facilities throughout
Sierra Leone;
(c) establish and maintain inventory control
procedures of essential medicines and medical
consumables at all levels of the public healthcare
system;
(d) undertake accurate and systematic recording,
monitoring and regular reporting of essential
medicines and medical consumables stock levels
The production and distribution of vaccines requires a high level of quality 
control throughout the entire supply chain. Policies must address the need for 
transportation, storage, and the secure supervision of vaccines to safeguard 
vaccine administration. Laws can provide requirements around licensure, 
supply, and production of vaccines to ensure the safety of these vaccines.
in all public health facilities throughout Sierra 
Leone; 
(e) engage, train and maintain the requisite
number and quality of staff that will ensure the
effective and efficient operation of the Unit;
( f) provide suitable storage and packing for
drugs procured by the Unit that will ensure that
drugs in storage and transit are secure and that
their quality, safety and efficacy are maintained
until delivery to the end-user;
(g) monitor, inspect and ensure that storage and
packing meet such standard as is. required for
the storage and transit of medicines and medical
consumables intended for public use;
(h) maintain vehicles and other means of trans-
port for the distribution of drugs; and
(i) do all such things as are necessary, expedi-
ent or conducive to the attainment of the general
object of the Unit and in accordance with the
Public Procurement Act, 2004 (Act No. 14 2004)
Sierra Leone has thus established the National Phar-
maceutical Procurement Units to ensure the appropri-
ate environment for the supply of essential medicines, 
and in Kenya, the law also requires an “effective moni-
toring and evaluation mechanism” to ensure proper 
protocols and necessitates transparency of informa-
tion relating to the storage and supply of drugs. 
C. Vaccine Administration
National laws can also include standards around the 
administration of vaccines. Policymakers can pre-
scribe immunization guidelines, including the most 
effective or efficient delivery methods, the immuniza-
tion schedule to ensure ideal coverage, the timeframes 
for getting back on-schedule after interruptions or 
delays in immunization, and even the publicity to 
increase immunization rates. To avoid adverse health 
effects, which can lead to public backlash against 
immunization and lower vaccination rates, laws can 
institute safe injection practices69 such as providers 
using clean needles and maintaining proper protec-
tive wear to avoid bodily fluids. Regulations can also 
ensure the safe disposal of biomaterials and the cre-
ation of workplace safety procedures. Where laws in 
the examined countries address vaccine administra-
tion, Liberia’s Public Health Law of 1976 created a 
“public immunizer” position, in which an immunizer 
is appointed by the Minister of Health and Social Wel-
fare to administer vaccines against communicable 
diseases.70 In managing vaccine administration, Mali’s 
Inter-ministerial Orders setting the List of Compul-
sory Vaccinations, Their Calendars and Conditions of 
Vaccine Administration of 2008 describes the neces-
 
sary steps in the administration of several vaccines.71 
These laws not only lessen the risk for potential harms 
to patients and providers, but they can also increase 
vaccination rates and herd immunity through regula-
tory efforts to facilitate both affordability through sub-
sidized or free vaccination and accessibility through 
prioritization of specific individuals.
1. subsidized or free vaccination
Where vaccine administration can be limited by the
individual costs of vaccination, many countries have
established legal guarantees of subsidized or free vac-
cinations to protect individual and public health. In
many cases, the burden of disease is often higher in
impoverished communities, and the ability to improve
the health of these communities can have potentially
larger impacts on the entire population.72
Numerous countries require that all vaccinations 
provided by the public vaccinator must be free of 
charge.73 
Public Health Act, 1935 (Uganda) 
43. No fee to be charged for a certificate or for
vaccination by public vaccinator. (1) No fee or
remuneration shall be charged to the person vac-
cinated by any public vaccinator for any certifi-
cate granted under this Act, nor for any vaccina-
tion done by him or her under this Act.
Vaccination Act, 1919 (Ghana) 
2. Free vaccination
(1) A public vaccinator shall vaccinate, free of
charge, the persons who present themselves or are
presented for the purpose, or persons who under
this Act are, or become, liable to be vaccinated.
Public Health Act, 1986 (Kenya) 110
(1) No fee or remuneration shall be charged to
the person vaccinated by any public vaccinator
for any certificate granted under this Act, nor for
any vaccination done by him in pursuance of
this Act.
In some cases, these vaccinations are free only to spe-
cific sub-populations, including children and pregnant 
women. Uniquely, the country of Togo has a provision 
that mandates an employer to cover costs for vaccina-
tions of any employee that has come into contact with 
any infection. 
2. prioritization of access to vaccination
Laws often prioritize access to vaccines for specific
individuals, especially in emergency situations and
during supply shortages. To assure a prioritization
scheme for immunization in advance of outbreaks, 
national regulators can consider vaccine availabil-
ity and the relative vulnerability of different popula-
tions, providing guidelines to prioritize access to vac-
cination for vulnerable groups and those who come in 
close contact with vulnerable groups. In addition to 
vulnerable individuals, specific professions — includ-
ing health care workers, firefighters, police, military, 
transportation, education, and sanitation workers 
— are often provided priority access to vaccination. 
While this assessment did not identify any national 
laws that establish a prioritization scheme for access 
to vaccinations, such laws are widespread in other 
countries, prioritizing vaccination access either at all 
times or in the context of a public health emergency.
D. Medicine Quality and Manufacturer Liability
Beyond the availability and accessibility of vaccina-
tions, an effective national immunization program
should include regulations to ensure that these medi-
cines meet proper quality standards.74 The creation of
a national medicine regulatory authority (NMRA) is
seen as an appropriate institution to assess the safety,
efficacy, and quality of vaccines. This institutional
authority can monitor drug manufacturing through
consistent inspections and post-marketing surveil-
lance — identifying poor quality and counterfeit
vaccines. Through vaccine registration, the Uganda
National Drug Policy and Authority Act of 199375 pro-
vides its national drug authority with the power to
approve and examine any new or imported drug.
National Drug Policy and Authority Act, 1993 
(Uganda) 
35. Drug regulation and registration of
specialties.
(1) The drug authority:
(a) may scientifically examine any drug for the
purposes of ascertaining efficacy, safety and
quality of that drug;
(b) shall institute a system for the approval of
drugs or drug combinations not included in the
national list of essential drugs.
36. Drug quality.
(1) The drug authority shall advise the Minister
on measures to be taken to ensure the quality
of drugs imported into or held in stock in the
country.
(2) The execution of the measures prescribed
shall be entrusted to bodies charged with the
importation and distribution of drugs.
(3) The inspection of drugs and measures pre-
scribed may be delegated to the chief of pharma-
ceuticals and health supplies or any other person
properly qualified in pharmaceuticals and 
health supplies.
Liberia similarly created the Liberia Medicines and 
Health Products Regulatory Authority in 2010 to 
ensure proper approval and registration of medicines, 
issuing registration licenses for all drugs and permits 
for all drug manufactures.76
To assure the continuing supply of vaccines from 
the private sector, where vaccine production has 
fallen in part because of legal liability for those who 
are harmed,77 national laws can support either liabil-
ity waivers for manufacturers or compensation pro-
grams for those who are harmed. While no examined 
country has pursued such liability protections, and 
experimental vaccines were deployed during the 2018 
Ebola epidemic without interruption,78 such liability 
laws have been developed in the United States and 
Europe to assure that lawsuits do not limit the supply 
of vaccines.79 
IV. Discussion
The results of this study highlight both the diversity of
approaches to immunization under national law and
the complete absence of immunization law across a
wide range of countries. Law reforms will be necessary 
to provide a foundation for expanding immunization
as a basis to prevent infectious disease.80 Immuniza-
tion law is not a panacea, but such laws can be part
of a larger set of national reforms that are necessary
to realize global health security and promote pub-
lic health.81 Where law is seen as an essential tool for
protecting the public’s health, legal epidemiology can
allow researchers to understand the impacts of these
policies on public health outcomes, providing justifi-
cation for public health law reforms.
In the United States, scholars, practitioners, and 
advocates have begun to conduct policy surveillance to 
inform policymakers and understand trends in state 
and federal policies to advance global health secu-
rity.82 Following the 2014-2015 Ebola outbreak, the 
US Center for Disease Control and Prevention (CDC) 
conducted a policy surveillance study across US states 
— looking at policies concerning Ebola screening and 
monitoring of asymptomatic individuals.83 This sys-
tematic policy surveillance compared state policies 
with CDC guidance and determined states to be either 
less or more restrictive then recommended. Based 
upon these results, the CDC advised state govern-
ments to harmonize policies with neighboring states 
to ensure legal clarity during times of infectious dis-
ease outbreaks. Comparative policy surveillance stud-
ies like these can be replicated internationally and 
policy recommendations can be tailored to the needs 
of each country.
In developing these national laws as a foundation to 
meet the GHSA, there is a need for rigorous empiri-
cal analysis of the impacts of such immunization law 
reforms on disease prevention outcomes. Legal epi-
demiology has rapidly become a path to empirical 
analysis of public health law, and immunization law 
provides a straightforward approach to legal epide-
miology across nations. Many nations collect public 
health data on immunization rates, alongside out-
come data on outbreak incidence and prevalence for a 
range of infectious diseases. These data provide legal 
epidemiologists — in collaboration with public health 
practitioners, researchers, lawyers, and governments 
— with the ability to examine both national laws (as 
an independent variable) and public health outcomes 
(as a dependent variable) to analyze the public health 
impact of vaccination laws within each country.84 Pol-
icy surveillance on immunization laws, paired with 
public health data on disease outbreaks, can allow 
policymakers to understand the positive and negative 
effects of legal attributes on public health and reform 
laws based upon empirical comparisons with other 
countries. Where regional health governance has been 
effective in promoting national health law reform,85 
the recent creation of the Africa CDC has established 
a regional governance framework to support countries 
in identifying best legal practices within Sub-Saharan 
Africa and providing an empirical basis to harmonize 
laws across countries. 
These reformed laws can assure that immunization 
policies provide the greatest benefit to public health 
while proving the least restrictive of individual rights. 
Although invaluable to the public’s health, immuniza-
tion law poses a risk of infringing of personal rights 
and freedoms.86 Echoing rights infringements during 
the 2014 Ebola outbreak in Liberia, where entire com-
munities were quarantined forcefully,87 the Demo-
cratic Republic of Congo recently acted through the 
police to bring an individual back to the hospital after 
he had left.88 These cases exemplify the tendency of 
infectious disease control policies to infringe on indi-
vidual rights, with these rights infringements under-
cutting public health efforts. Especially where the law 
provides for mandatory vaccination, there is a poten-
tial for derogations from individual rights, and it will 
be necessary to assure that human rights are protected 
under immunization law. Where the state is obligated 
under international law to ensure a balance between 
the goals of public health and the rights of the indi-
vidual,89 comparisons across national legal practices 
can provide understanding of the appropriate balance 
between public health and human rights, making vac-
cinations the norm and exemptions a rare occurrence. 
While there is no need to standardize immuniza-
tion law globally — with each country having distinct 
disease control concerns that can be addressed within 
contextualized national policies — policymakers can 
look to models in other countries to share lessons and 
support reforms. This research has identified gaps 
in national immunization laws, and each country 
can look to other national approaches in filling these 
gaps, developing the public health law reforms neces-
sary to strengthen public health systems. As a foun-
dation for legal epidemiology research, policymakers 
can continuously work with public health practitio-
ners, researchers, and lawyers to assure that any law 
adopted is continuously improving public health. 
Conclusion
With the world at increasing risk of infectious disease, 
policymakers must create robust national health sys-
tems that can support efforts to prevent disease. Where 
a lack of immunization can create an opening for an 
infectious disease outbreak, which can quickly spread 
throughout a rapidly globalizing world, vaccines are 
an important tool for global health security and public 
health promotion. The GHSA has provided a model 
for key aspects of infectious disease control, but for 
the GHSA to function appropriately, national govern-
ments must develop legal frameworks to implement 
GHSA imperatives. Through policy surveillance of 
immunization laws across various countries, research-
ers can play a central role in assisting policymakers to 
understand the range of policy approaches to expand 
immunization. Supported by legal epidemiology, it 
is possible for researchers to combine policy surveil-
lance with epidemiological data, clarifying the impact 
of these laws on public health and providing empirical 
justification for public health law reform. By assessing 
the role of law as a determinant of public health, such 
research can catalyze necessary law reforms, allowing 
national policymakers to create the legal structures 
needed for global health security.
Note
This research uses data collected under Cooperative Agreement/
Contract No. 200-2010-35770, Task Order 13 funded by Centers 
for Disease Control and Prevention (CDC).
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